DEFENDO- Study to evaluate safety and efficacy of ophthalmic solution (Oxervate) in patients with Stage 1 Neurotrophic Keratitis (NK)
Enrolling By Invitation
99 years or below
All
Phase
N/A
5 participants needed
1 Location
Brief description of study
This clinical study will be a multi-center, open label, prospective study of 8 weeks of treatment with 24 weeks of follow-up to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered as one drop in the affected eye(s), 6 times per day at 2-hour intervals, for eight weeks in patients with Stage 1 Neurotrophic Keratitis (NK).
Participants will include patients seen within the Department of Ophthalmology at Penn Medicine. Referrals from physicians may also be considered.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Neurotrophic Keratitis
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844236
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
